Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Business17 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business19 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
General16 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips
-
Business16 hours agoHere’s what analysts expect for the BHP share price in the coming year